Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide for Refractory Antibody-Mediated Rejection in Kidney Transplantation
NCT01630538Phase 2Terminated
- Sponsor
- University of Manitoba
- Start
- Jun 2013
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cyclophosphamide in antibody mediated rejection (AMR), sponsored by University of Manitoba. Started Jun 2013; status: terminated.
02
Drugs
cyclophosphamide
03
Conditions
antibody mediated rejection (AMR)
Beyond the preview
Go deeper on NCT01630538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01630538.